Eubiotic effects of rifaximin are associated with reduced abdominal pain in symptomatic uncomplicated diverticular disease: results of an observational cohort study | BMC Gastroenterology
To our knowledge, this study is the first to evaluate the long-term (i.e., 6 months) effects of rifaximin on the gut microbiota of SUDD patients. Here we show that rifaximin significantly reduced the severity of abdominal pain, which is consistent with previous studies. [9,10,11,12]. Treatment with rifaximin over 6 months was not associated with significant […]